Given that genetic alterations in the MAPK and PI3K/AKT pathways are significant drivers of their activation [133, 134], it would be valuable to observe how ROS interacts with these genetic modifications to facilitate the initiation and progression of thyroid cancer. This evidence concerns the gene AKT1 and thyroid gland carcinoma.